|Bid||30.650 x 1200|
|Ask||30.700 x 800|
|Day's Range||30.275 - 31.050|
|52 Week Range||16.100 - 32.200|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK, June 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of NovoCure ...
Novocure (NVCR) will present today for the first time the design of its phase 3 pivotal trial of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 in Chicago. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die. INNOVATE-3, a prospective, open-label study, will include 540 patients with recurrent, platinum-resistant ovarian cancer.
Dr. David T. Hung and Sherilyn D. McCoy, both experienced executive leaders, were elected to Novocure’s board at the annual general meeting of shareholders on May 31. Gert Lennart Perlhagen is retiring from the board after 15 years of service. “We are extremely pleased to welcome David and Sheri to our board,” said Bill Doyle, Novocure’s Executive Chairman.
WallStEquities.com has selected the following Medical Appliances and Equipment stocks for review this morning: Lantheus Holdings Inc. (NASDAQ: LNTH), Nevro Corp. (NYSE: NVRO), NovoCure Ltd (NASDAQ: NVCR), and NuVasive Inc. (NASDAQ: NUVA). North Billerica, Massachusetts headquartered Lantheus Holdings Inc.'s shares gained slightly by 0.35%, closing Wednesday's trading session at $14.20.
Novocure today reported financial results for the quarter and year ended March 31, 2018, highlighting year-over-year growth in active patients and net revenues. Novocure is a global oncology company developing a proprietary platform called Tumor Treating Fields for the treatment of solid tumor cancers.
NEW YORK, NY / ACCESSWIRE / April 26, 2018 / Novocure Ltd. (NASDAQ: NVCR ) will be discussing their earnings results in their Q1 Earnings Call to be held on April 26, 2018 at 8:00 AM Eastern Time. To listen ...
NEW YORK, April 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Stock Monitor: Neovasc Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on NovoCure Ltd (NASDAQ: NVCR ). If you want access ...
Novocure announced today positive top-line results from its STELLAR phase 2 pilot trial in mesothelioma demonstrating clinically meaningful improvements in overall survival and progression free survival among patients who received Tumor Treating Fields plus standard of care chemotherapy, pemetrexed and cisplatin or carboplatin, compared to historical control data of patients who received standard of ...
Novocure announced today that new data on Tumor Treating Fields will be presented at the American Association for Cancer Research Annual Meeting 2018, which will be held April 14 through April 18, in Chicago.
Novocure announced today that it will report financial results for the first quarter 2018 on Thursday, April 26, 2018, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months ended March 31, 2018, at 8 a.m.
Novocure announced today that the National Comprehensive Cancer Network has updated its clinical practice guidelines to recommend Optune® in combination with temozolomide as a category 1 treatment for newly diagnosed glioblastoma in its globally recognized Clinical Practice Guidelines in Oncology for Central Nervous System Cancers.
Stock Monitor: CryoLife Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 19, 2018 / Active-Investors.com has just released a free research report on NovoCure Ltd (NASDAQ: NVCR ). If you want access ...
Novocure announced today 35 presentations on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2018, April 14 through April 18, in Chicago.
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / Novocure Ltd. (NASDAQ: NVCR ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 22, 2018 at 8:00 AM Eastern Time. ...
Novocure today reported financial results for the quarter and year ended December 31, 2017, highlighting year-over-year and sequential growth in active patients and net revenues.
Novocure announced today that it has entered into a $150 million term loan agreement with BioPharma Credit PLC , an investment fund managed by Pharmakon Advisors, LP, with proceeds used to pay in full Novocure’s existing $100 million term loan debt and fund working capital.
WALTHAM, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, ...
Novocure announced today that a detailed quality of life analysis of Novocure’s EF-14 phase 3 pivotal trial of Optune in combination with temozolomide for the treatment of newly diagnosed glioblastoma has been published in JAMA Oncology.
Novocure today reported operating statistics and preliminary, unaudited revenue for the fourth quarter and full year 2017. Novocure plans to discuss these results with investors at the 36th Annual J.P.
Novocure announced today that it will participate in the 36th Annual J.P. Morgan Healthcare Conference on January 10, 2018, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts.
Novocure announced today that the final analysis of its phase 3 pivotal trial of Optune in combination with temozolomide for the treatment of newly diagnosed glioblastoma has been published in the Journal of the American Medical Association .
Novocure announced today that it has received a U.S. Food and Drug Administration Investigational Device Exemption approval to initiate its PANOVA 3 clinical trial.